Er2 Negative Metastatic Breast Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Er2 negative metastatic breast cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Er2 Negative Metastatic Breast Cancer Today - Breaking & Trending Today

Dr Wander on Genomic Alterations in ER+/HER2– Metastatic Breast Cancer

Seth Wander, MD, PhD, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial of lasofoxifene plus abemaciclib. ....

United States , Harvard Medical School , Seth Wander , Massachusetts General Hospital , Patients With Estrogen Receptor Positive , Er2 Negative Metastatic Breast Cancer , Elaine 2 Trial , Lasofoxifene Plus Abemaciclib ,

Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBC

Avan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings. ....

Avan Armaghani , Moffitt Cancer Center , Patients With Hormone Receptor Positive , Er2 Negative Metastatic Breast Cancer , De Escalation , Ascent 03 , Ascent 04 ,

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer. ....

Saram Tolaney , Susanf Smith Center , Dana Farber Cancer Institute , Division Of Breast Oncology , Medicine At Harvard Medical School , Breast Oncology , Harvard Medical , Sacituzumab Govitecan , Hormone Receptor Positive , Er2 Negative Metastatic Breast Cancer , Overall Survival , Tropics 02 Trial , Asco Annual Meeting ,

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial. ....

Baden Wüberg , Frederik Marm , Gilead Sciences , Breast Cancer Annual Congress , Cancer Annual , Cancer Annual Congress , Breast Cancer , Esmo Breast Cancer Congress , Sacituzumab Govitecan , Phase 3 Tropics 02 Trial Nct03901339 , Hormone Receptor Positive , Er2 Negative Metastatic Breast Cancer , Ugt1a1 Status ,

OP-1250 Plus Palbociclib Demonstrates Activity, Safety in HR+/HER2– Metastatic Breast Cancer

The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. ....

United States , Western Australia , Marlene Chan , Breast Cancer Annual Congress , Cancer Annual , Hollywood Private Hospital , Cancer Annual Congress , Op 1250 , Hormone Receptor Positive , Er2 Negative Metastatic Breast Cancer , Breast Cancer , Hr Positive Breast Cancer , Esmo Breast Cancer Congress ,